Rilpivirine Injectable Suspension

DRUG3 trials

Sponsors

ViiV Healthcare, University of Zurich

Conditions

HIV InfectionsHuman Immunodeficiency Virus Type 1 (HIV-1)

Phase 3

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

Active, not recruitingNCT03299049

ViiV HealthcareHIV Infections

Start: 2017-10-27End: 2029-12-31Updated: 2025-08-22

A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

CompletedNCT05896761

ViiV HealthcareHuman Immunodeficiency Virus Type 1 (HIV-1)

Start: 2021-10-28End: 2022-08-23Updated: 2023-09-18

Unknown Phase

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

RecruitingNCT06405464

University of ZurichHIV Infections

Start: 2022-03-01End: 2026-06-30Target: 600Updated: 2024-05-08

Related Papers

Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.

2024-07-0111 citations

Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP

Antimicrobial Agents and Chemotherapy2024-05-067 citations

Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96

HIV Medicine2023-12-261 citations

Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.

2023-07-1410 citations

Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.

2022-05-042 citations

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.

2022-02-079 citations

875. Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1 Infected Participants

Open Forum Infectious Diseases2021-11-01

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

AIDS2021-10-1334 citations

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

2021-10-11103 citations

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

AIDS2021-07-1392 citations

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).

2021-05-3156 citations

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

2020-12-09259 citations

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

JAIDS Journal of Acquired Immune Deficiency Syndromes2020-08-21135 citations